Icagen, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally-administered small molecule drugs that modulate ion channel targets. The company’s programs include ICA-17043, a Phase III clinical trial product, which is an inhibitor of the Gardos channel for the chronic prophylactic treatment of sickle cell disease; a lead compound under preclinical studies for epilepsy and neuropathic pain; a phase I clinical trial compound for atrial fibrillation; and compounds in preclinical studies for dementia, including Alzheimer’s disease. It also conducts drug discovery programs on therapeutics for pain disorders,...
To see the headquarters in Google Street View &trade, drag this yellow guy: over to the red pointer:
Contact Information:
Business Address:
-
Mailing Address:
Business Address
4222 EMPEROR BLVD
SUITE 350
DURHAM NC 27703
919-941-5206
ICAGEN INC CIK #: 0000902622 (see all company filings)
SIC : 2834 - PHARMACEUTICAL P
DECEMBER 20, 2010
*************
TOP MID-DAY ALERTS
*************
TODAYS ALERT UPDATES -
AEZS - UP 5% @ $1.93
ITMN - UP 5% @ $36.60
SNSS - UP 14% @ $0.44
SEE THIS MORNINGS ALERT FOR DETAILS
*************
BREAKOUT read more
To see the headquarters in Google Street View &trade, drag this yellow guy: 
over to the red pointer: 
DECEMBER 20, 2010
*************
TOP MID-DAY ALERTS
*************
TODAYS ALERT UPDATES -
AEZS - UP 5% @ $1.93
ITMN - UP 5% @ $36.60
SNSS - UP 14% @ $0.44
SEE THIS MORNINGS ALERT FOR DETAILS
*************
BREAKOUT read more
